🔴 Tvardi Therapeutics is trading 5% down with no clear company-specific catalyst identified

Tvardi Therapeutics is trading at $1.22 (-5.08%) during the September 30, 2026 session, with no clear company-specific catalyst identified.

• The latest company announcement located was September 24 preclinical research on STAT3 inhibitors in ulcerative colitis, not a new September 30 update.
• Broader market indicators were mixed and did not clearly explain the decline; the supplied price context shows a pullback following sharp recent price swings.